Login to Your Account

Alzheimer's Drug Moving Ahead Positively, Boosting Elan's Stock

By Aaron Lorenzo

Tuesday, May 22, 2007
Partners Elan Corp. plc and Wyeth said they plan to begin Phase III testing of their lead immunotherapeutic candidate bapineuzumab (AAB-001) for mild to moderate Alzheimer's disease in the second half of this year, boosting excitement around the disease-modifying agent. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription